Impaired instrumental learning in Spred1-/- mice, a model for a rare RASopathy
- PMID: 33624414
- DOI: 10.1111/gbb.12727
Impaired instrumental learning in Spred1-/- mice, a model for a rare RASopathy
Abstract
RASopathies are neuro-cardio-facio-cutaneous disorders stemming from mutations in genes regulating the RAS-MAPK pathway. Legius syndrome is a rare RASopathy disorder caused by mutations in the SPRED1 gene. SPRED1 protein negatively regulates activation of Ras by inhibiting RAS/RAF and by its interaction with neurofibromin, a Ras GTPase-activating protein (RAS-GAP). Cognitive impairments have been reported in Legius syndrome as well as in other RASopathy disorders. Modelling these cognitive deficits in a Spred1 mouse model for Legius syndrome has demonstrated spatial learning and memory deficits, but other cognitive domains remained unexplored. Here, we attempted to utilize a cognitive touchscreen battery to investigate if Spred1-/- mice exhibit deficits in other cognitive domains. We show that Spred1-/- mice had heterogeneous performance in instrumental operant learning, with a large subgroup (n = 9/20) failing to reach the standard criterion on touchscreen operant pretraining, precluding further cognitive testing. To examine whether targeting the RAS-MAPK signalling pathway could rescue these cognitive impairments, Spred1-/- mice were acutely treated with the clinically relevant mitogen-activated protein kinase (MEK) inhibitor PD325901. However, MEK inhibition did not improve their instrumental learning. We conclude that Spred1-/- mice can model severe cognitive impairments that cannot be reversed in adulthood.
Keywords: MEK inhibition; RAS-MAPK; RASopathy; autism spectrum disorder; cognitive impairment; instrumental learning; mouse; neurodevelopmental disorder; spred1; touchscreen test.
© 2021 International Behavioural and Neural Genetics Society and John Wiley & Sons Ltd.
References
REFERENCES
-
- Ryu H-H, Lee Y-S. Cell type-specific roles of RAS-MAPK signalling in learning and memory: implications in neurodevelopmental disorders. Neurobiol Learn Mem. 2016;135:13-21. https://doi.org/10.1016/j.nlm.2016.06.006.
-
- Borrie SC, Brems H, Legius E, Bagni C. Cognitive dysfunctions in intellectual disabilities: the contributions of the Ras-MAPK and PI3K-AKT-mTOR pathways. Annu Rev Genomics Hum Genet. 2017;18(1):115-142. https://doi.org/10.1146/annurev-genom-091416-035332.
-
- Shilyansky C, Lee YS, Silva AJ. Molecular and cellular mechanisms of learning disabilities: a focus on NF1. Annu Rev Neurosci. 2010;33:221-243. https://doi.org/10.1146/annurev-neuro-060909-153215.
-
- Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology. 2005;65(7):1037-1044. https://doi.org/10.1212/01.wnl.0000179303.72345.ce.
-
- Rowbotham I, Pit-ten Cate IM, Sonuga-Barke EJS, Huijbregts SCJ. Cognitive control in adolescents with neurofibromatosis type 1. Neuropsychology. 2009;23(1):50-60. https://doi.org/10.1037/a0013927.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
